Deals this week: Ixaltis, Arbutus Biopharma, Gesynta Pharma

French specialist pharmaceutical company Ixaltis has signed an agreement with Swiss biopharmaceutical company Xigen for worldwide rights to a compound being developed by the latter, targeting urogenital diseases.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news